The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why should we use MRD assessment post hematopoietic stem cell transplantation?

Sep 18, 2020

The virtual AML Hub Satellite Symposiumat the 46 thAnnual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of expertsto discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future. Professor Charles Craddock, University of Birmingham, Birmingham, UK, presented the topic ‘Why should we use MRD assessment post hematopoietic stem cell transplantation?’

During his talk, Professor Charles Craddock focuses on post-transplant strategies, such as maintenance therapy and donor lymphocyte infusion, to improve transplant outcome in patients with AML. He outlines how MRD-guided treatment decisions can prevent or delay relapse after stem cell transplantation in patients with AML.

The first AML Hub Satellite Symposium: Watch here!

Welcome to the AML Hub Satellite Symposium.

Please take a moment to complete the survey and answer the following question to help us gauge your current understanding of the use of MRD assessment after stem cell transplantation.